ERYTECH provides an update on its regulatory activity
Cessation of activities in view of submitting an application for approval of Graspa® in the treatment of patients with Acute Lymphoblastic Leukemia (ALL)
Ongoing assessment of strategic partnership options
Lyon (France), and Cambridge, MA (US) on August 24, 2022 – ERYTECH Pharma (Euronext & Nasdaq: ERYP), a clinical-stage biopharmaceutical company that develops innovative therapies by encapsulating drugs in red blood cells (RBCs), announces update on its regulatory activity and announces its decision, following responses from the Food and Drug Administration (FDA), to no longer seek approval of Graspa® for the treatment of ALL patients with hypersensitivity to pegylated asparaginase